| |
|
| |
|
AmDPB, Diagnostics. 28-30 July, Belem, Brazil |
|
| |
The America's Dengue Prevention Board will meet July 28-30 in Belem, Brazil to discuss issues surrounding dengue diagnostics. A companion meeting on this topic was held by the Asia Pacific Dengue Prevention Board in Bangkok in December 2007, and the results of the two meetings will be combined to reflect the thinking of both regions.
|
| |
|
1st Americas Dengue Research Network meeting to be held in Recife, Brazil, 23-25 July |
|
| |
PDVI has conducted a series of Research Network meetings in the Asia Pacific region, and it has always been the intent to have an Americas meeting similar to the ones conducted in Asia and to alternate the Americas and Asia meetings, such that each year there would be a PDVI co-sponsored Regional Research Network meeting. Planning for the first Americas meeting began in 2007 and it will be held 23-25 July, 2008 in Recife, Brazil; co-sponsors include the Oswaldo Cruz Foundation (FIOCRUZ) and the Brazilian Ministry of Health. The objective of this biannual meeting is to provide a forum for research progress in vaccines, therapeutics and diagnostics covering such topics as viral genomics, structure and assembly; virus entry and cell receptors; innate immunity and host responses; animal models; antiviral targets and cell-based screens; pathogenesis; protective immunity and antibody dependent enhancement (ADE); and diagnostics and clinical /epidemiological studies.
|
| |
|
|
The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world's poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Program in 1997, the IVI operates under a treaty signed by 40 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul. For more information, please visit www.ivi.int
|
|
| |
|
 |
| |
|
